Results 1 to 10 of about 6,467,216 (270)
Alzheimer disease [PDF]
Nature Reviews Disease Primers, 2021 Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.David S. Knopman, Helene Amieva, Ronald C. Petersen, Gäel Chételat, David M. Holtzman, Bradley T. Hyman, Ralph A. Nixon, David T. Jones +7 moreopenaire +4 more sourcesAlzheimer’s disease [PDF]
Current Biology, 2018 The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later Grøntvedt, G., Navarro Schröder, T., Sando, S., White, L., Bråthen, G., Doeller, C. ; https://orcid.org/0000-0003-4120-4600 +5 moreopenaire +5 more sourcesEpidemiology of Alzheimer's disease : occurrence, determinants, and strategies toward intervention
, 2009 More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. In both developed and developing nations, Alzheimer's disease has had tremendous impact on the affected individuals, caregivers, and society.Qiu, C, Kivipelto, M, von Strauss, Eva,core +9 more sourcesA data-driven examination of apathy and depressive symptoms in dementia with independent replication [PDF]
, 2023 Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or ...Schuff, N, Stern, Y, Reinwald, LT, Carroll, M, Ward, C, Ballard, C, Jagust, W, Mathis, C, Schneider, LS, Teodoro, L, Meyer, JV, Gessert, D, Harvey, D, Dolen, S, Mintun, MA, Weiner, M, Carter, R, Leon, S, Ances, B, Householder, E, Rountree, S, Gunter, J, Brewer, J, Toga, AW, Schneider, S, Landau, S, Creese, B, Bell, KL, Aisen, P, Shaw, LM, Senjem, M, Jack, CR, Melendez-Torres, GJ, Sather, T, Nho, K, Shen, L, Dang, M, Borowski, B, DeCArli, C, Molchan, S, Beckett, L, Frank, R, Liu, E, Foroud, TM, Cairns, NJ, Korecka, M, Oliver, A, Lord, JL, Koeppe, RA, Knopman, D, Fleisher, A, Walter, S, Vasconcelos Da Silva, M, Fox, N, Albers, CS, Beccera, M, Vemuri, P, Lee, V, Lind, B, Green, RC, Figurski, M, Kim, S, Snyder, PJ, Johnson, K, Heidebrink, JL, Pawluczyk, S, Thomas, RG, Foster, N, Jones, D, Honig, LS, Petersen, R, Bernstein, M, Chowdhury, M, Spann, BM, Kaye, J, Marson, D, Montine, T, Kantarci, K, Trojanowki, JQ, Kachaturian, Z, Testad, I, Reiman, EM, Chen, K, Mason, SS, Crawford, K, Van der Swag, H, Donohue, M, Jiminez, G, Morris, J, Doody, RS, Potkin, S, Kelley, F, Ismail, Z, Saykin, AJ, Quinn, J, Thompson, P, Neu, S +96 morecore +1 more sourceAlzheimer’s disease [PDF]
Network: Computation in Neural Systems, 2011 Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration. Eponymic diseases of the nervous system such as Alzheimer's, Parkinson's, and Huntington's diseases that were long characterized by mechanistic ignorance have yielded striking progress ...Adam, Gazzaley, Scott A, Smallopenaire +4 more sourcesAlzheimer's disease [PDF]
Journal of Neurology, Neurosurgery & Psychiatry, 2000 Use of valid diagnostic criteria is extremely important in the recognition of Alzheimer's disease (AD). Patients with mild to moderate Alzheimer's disease should be started on a cholinesterase inhibitor and possibly anti-inflammatory agents, antioxidants (vitamin E or selegiline), and estrogen replacement therapy (for postmenopausal women)., Schachter, , Davis +8 more sourcesEffects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition [PDF]
, 2022 Introduction: It is important to understand which biological processes change with aging, and how such changes are associated with increased Alzheimer's disease (AD) risk. We studied how cerebrospinal fluid (CSF) proteomics changed with age and tested if Soininen, Hilkka,, Lovestone, S., Blennow, Kaj,, Vos, Stephanie JB, Frans Verhey, Dobricic, Valerija,, Teunissen, Charlotte E, Scheltens, Philip,, Vos, S.J.B., Freund‐Levi, Yvonne, Charlotte E. Teunissen, Scheltens, P., Bos, Isabelle, Pieter Jelle Visser, Freund-Levi, Y., Simon Lovestone, Visser, Pieter Jelle,, Vandenberghe, Rik,, Johan Gobom, Teunissen, C. E., Hallikainen, M., Rik Vandenberghe, Laakso, M., Vos, S. J. B., Teunissen, C.E., Kuusisto, J., Bos, I., Blennow, K., Julius Popp, Martinez-Lage, Pablo, Vandenberghe, Rik, Stephanie J.B. Vos, Wesenhagen, K. E. J., Philip Scheltens, Bos, Isabelle,, Vos, Stephanie J. B.,, Kaj Blennow, Tijms, Betty M, Vos, Stephanie J.B., Dobricic, Valerija, Soininen, Hilkka, Pikkarainen, M., Wesenhagen, K.E.J., Tijms, B. M., Vos, SJB, Gobom, J., Betty M. Tijms, Martinez‐Lage, Pablo, Vandenberghe, R., Scheltens, Philip, Tijms, B.M., Johannes Streffer, Merja Hallikainen, Kuusisto, Johanna, Henrik Zetterberg, Bertram, Lars,, Zetterberg, H., Magda Tsolaki, Markku Laakso, Soininen, H., Hallikainen, Merja,, Pikkarainen, Maria,, Laakso, Markku,, Tijms, Betty M., Teunissen, Charlotte E., Teunissen, Charlotte E.,, Tijms, Betty M.,, Yvonne Freund‐Levi, Wesenhagen, Kirsten EJ, Valerija Dobricic, Isabelle Bos, Kirsten E.J. Wesenhagen, Lars Bertram, Zetterberg, Henrik,, Bertram, Lars, Hallikainen, Merja, Freund-Levi, Yvonne, Visser, Pieter Jelle, Wesenhagen, Kirsten E.J., Hilkka Soininen, Wesenhagen, KEJ, Maria Pikkarainen, Gobom, Johan,, Popp, Julius, Lovestone, Simon, Martinez-Lage, P., Streffer, Johannes, Verhey, F., Visser, P.J., Tsolaki, Magda,, Pablo Martinez‐Lage, Visser, P. J., Tsolaki, M., Martinez-Lage, Pablo,, Popp, Julius,, Tsolaki, Magda, Laakso, Markku, Verhey, Frans, Lovestone, Simon,, Zetterberg, Henrik, Pikkarainen, Maria, Freund-Levi, Yvonne,, Streffer, J., Johanna Kuusisto, Gobom, Johan, Alzheimer's Disease Neuroimaging Initiative, Dobricic, V., Verhey, Frans,, Streffer, Johannes,, Blennow, Kaj, Popp, J., Wesenhagen, Kirsten E. J.,, Kuusisto, Johanna,, Bertram, L., Tsolaki, M, Bos, I, Martinez-Lage, P, Popp, J, Gobom, J, Verhey, F, Freund-Levi, Y, Vandenberghe, R +121 morecore +1 more sourceBarriers and facilitators to participating in Alzheimer's disease biomarker research in black and white older adults
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Introduction The study examined Black and White prospective participants’ views of barriers to and facilitators of participation in Alzheimer's disease (AD) biomarker research.Johanne Eliacin, Angelina J. Polsinelli, Francine Epperson, Sujuan Gao, Sarah Van Heiden, Glenda Westmoreland, Ralph Richards, Mollie Richards, Christopher Campbell, Hugh Hendrie, Shannon L. Risacher, Andrew J. Saykin, Sophia Wang +12 moredoaj +1 more sourceIsoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation
iScience, 2021 Summary: It has been suggested that aberrant activation of glycogen synthase kinase-3-beta (GSK-3β) can trigger abnormal tau hyperphosphorylation and aggregation, which ultimately leads to neuronal/synaptic damage and impaired cognition in Alzheimer ...Ana Claudia Amaral, Beatriz G. Perez-Nievas, Michael Siao Tick Chong, Alicia Gonzalez-Martinez, Herminia Argente-Escrig, Sara Rubio-Guerra, Caitlin Commins, Serra Muftu, Bahareh Eftekharzadeh, Eloise Hudry, Zhanyun Fan, Prianca Ramanan, Shuko Takeda, Matthew P. Frosch, Susanne Wegmann, Teresa Gomez-Isla +15 moredoaj +1 more sourceThe Association of Amyloid-β and Tau With Synaptic Dysfunction in Alzheimer's Disease. [PDF]
Ann Clin Transl NeurolABSTRACT Objective
To clarify the relative contributions of amyloid and tau to synaptic dysfunction in Alzheimer's disease (AD). Methods
We included 109 cognitively unimpaired and impaired individuals from the Geneva Memory Center with available CSF synaptic biomarkers (neurogranin, SNAP‐25, GAP‐43). Participants were stratified according to amyloid (A)Roveta F, Mendes AJ, Garibotto V, Boccalini C, Lathuiliere A, Rainero I, Rubino E, Zetterberg H, Ashton NJ, Ribaldi F, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative. +11 moreeuropepmc +2 more sources
